Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients.

Background and aim: Pharmacotherapy for alcohol use disorder (AUD) is recommendable, but under‐used, possibly due to deficient knowledge of medications. This study aimed to investigate the real‐world effectiveness of approved pharmacological treatments (disulfiram, acamprosate, naltrexone and nalmef...

Descripción completa

Detalles Bibliográficos
Publicado en:Addiction Vol. 116; no. 8; pp. 1990 - 1999
Autores principales: Heikkinen, Milja, Taipale, Heidi, Tanskanen, Antti, Mittendorfer‐Rutz, Ellenor, Lähteenvuo, Markku, Tiihonen, Jari
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Aug2021
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=151210161&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 151210161
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09652140
        AIO
      jtl: Addiction
      issn: 09652140
      maglogo: Y
    pubinfo:
      dt: Aug2021
      vid: 116
      iid: 8
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        151210161
        148091475
        151210161
        151210161
        10.1111/add.15384
        151210161
      ppf: 1990
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients.
      aug:
        au:
          Heikkinen, Milja
          Taipale, Heidi
          Tanskanen, Antti
          Mittendorfer‐Rutz, Ellenor
          Lähteenvuo, Markku
          Tiihonen, Jari
        affil: Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland
      sug:
        subj:
          Alcohol-Related Disorders Drug Therapy
          Alcohol Deterrents Therapeutic Use
          Treatment Outcomes
          Sweden
          Human
          Adolescence
          Adult
          Middle Age
          Disulfiram
          Acamprosate Calcium
          Naltrexone
          Antianxiety Agents, Benzodiazepine
          Prospective Studies
          Hospitalization
          Multivariate Analysis
          Cox Proportional Hazards Model
          Regression
          Confidence Intervals
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
      ab: Background and aim: Pharmacotherapy for alcohol use disorder (AUD) is recommendable, but under‐used, possibly due to deficient knowledge of medications. This study aimed to investigate the real‐world effectiveness of approved pharmacological treatments (disulfiram, acamprosate, naltrexone and nalmefene) of AUD. Design A nation‐wide, register‐based cohort study. Setting: Sweden. Participants: All residents aged 16–64 years living in Sweden with registered first‐time treatment contact due to AUD from July 2006 to December 2016 (n = 125 556, 62.5% men) were identified from nation‐wide registers. Measurements The main outcome was hospitalization due to AUD. The secondary outcomes were hospitalization due to any cause, alcohol‐related somatic causes, as well as work disability (sickness absence or disability pension), and death. Mortality was analysed with between‐individual analysis using a traditional multivariate‐adjusted Cox hazards regression model. Recurrent outcomes, such as hospitalization‐based events and work disability, were analysed with within‐individual analyses to eliminate selection bias. Findings Naltrexone combined with acamprosate [hazard ratio (HR) = 0.74; 95% confidence interval (CI) = 0.61–0.89], combined with disulfiram (HR = 0.76, 95% CI = 0.60–0.96) and as monotherapy (HR = 0.89, 95% CI = 0.81–0.97) was associated with a significantly lower risk of AUD‐hospitalization compared with no use of AUD medication. Similar results were found for risk of hospitalization due to any cause. Benzodiazepine use and acamprosate monotherapy were associated with an increased risk of AUD‐hospitalization (HR = 1.18, 95% CI = 1.14–1.22 and HR = 1.10, 95% CI = 1.04–1.17, respectively). No statistically significant effects were found for work disability or mortality. Conclusions: Naltrexone as monotherapy and when combined with disulfiram and acamprosate appears to be associated with lower risk of hospitalization due to any and alcohol‐related causes, compared with no use of alcohol use disorder (AUD) medication. Acamprosate monotherapy and benzodiazepine use appear to be associated with increased risk of AUD‐associated hospitalization.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N